List of Excipients in Branded Drug RILUZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rising Pharmaceuticals Inc	RILUZOLE	riluzole	64980-191	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Rising Pharmaceuticals Inc	RILUZOLE	riluzole	64980-191	CELLULOSE, MICROCRYSTALLINE
Rising Pharmaceuticals Inc	RILUZOLE	riluzole	64980-191	CROSCARMELLOSE SODIUM
Rising Pharmaceuticals Inc	RILUZOLE	riluzole	64980-191	HYPROMELLOSES

Generic Drugs Containing RILUZOLE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	riluzole	0378-4145	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Mylan Pharmaceuticals Inc	riluzole	0378-4145	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	riluzole	0378-4145	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	riluzole	0378-4145	HYPROMELLOSE

What are the Most Frequently-Used Excipients in RILUZOLE?

# Of NDCs	Excipient
4	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
2	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
8	CELLULOSE, MICROCRYSTALLINE
2	CITRIC ACID MONOHYDRATE

Riluzole Excipient Strategy and Commercial Opportunities in Oral Solid, Liquid, and Film Formulations

Last updated: August 12, 2026

Riluzole is a mature small-molecule ALS therapy with limited opportunity at the active-ingredient level but meaningful commercial potential in differentiated delivery systems. The strongest formulation opportunities target dysphagia, feeding-tube administration, taste masking, dose flexibility, storage stability, and simplified adherence. Generic 50 mg tablets face intense price competition. Oral suspensions and oral films have greater differentiation potential because they address administration barriers that conventional tablets do not.

What is the current FDA status of riluzole products?

Riluzole is FDA-approved for amyotrophic lateral sclerosis and is marketed in several dosage forms:

Product	Dosage form	Strength	Administration advantage	Regulatory position
Rilutek and generic riluzole	Tablet	50 mg	Conventional oral dosing	Mature, multisource market
Tiglutik	Oral suspension	50 mg/10 mL	Liquid dosing and feeding-tube suitability	NDA product
Exservan	Oral film	50 mg	Dissolves on the tongue; designed for dysphagia	NDA product
Generic oral suspension or film	Potential ANDA or 505(b)(2) products	Product-dependent	May compete through formulation differentiation	Opportunity depends on reference-product patents and FDA requirements

The approved adult regimen is 50 mg twice daily, taken at least one hour before or two hours after meals. Food can alter riluzole exposure, making dosing instructions and formulation performance important commercial considerations [1][2][3].

Riluzole is a small molecule, not a biologic. Biosimilar regulation does not apply. Competitive entry occurs through abbreviated new drug applications, 505(b)(2) applications, formulation development, and, where applicable, Paragraph IV patent challenges.

Which excipients are used in approved riluzole formulations?

The principal commercial benchmarks are the tablet, suspension, and oral-film products. Their excipient systems show three different development strategies.

Riluzole tablets

Riluzole tablets generally use a conventional immediate-release matrix containing:

• Dibasic calcium phosphate or another diluent
• Microcrystalline cellulose
• Croscarmellose sodium as a disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Film-coating components, where applicable

The tablet strategy is low cost and manufacturing-efficient. Its limitations are clinically relevant: patients with ALS may develop dysphagia, impaired swallowing coordination, fatigue, sialorrhea, or dependence on enteral feeding.

Tiglutik oral suspension

Tiglutik is a 50 mg/10 mL riluzole oral suspension. Its formulation requires excipients that maintain dose uniformity during storage and use. A commercial suspension typically depends on:

• Suspending or viscosity-building polymers
• Wetting agents
• Sweeteners
• Flavoring agents
• Preservatives
• Buffers or pH-adjusting agents
• Purified water

The key technical risks are sedimentation, caking, redispersibility, microbial control, viscosity drift, and dose-measurement accuracy. The product label instructs shaking before use, which confirms that physical homogeneity is a core performance attribute [2].

Exservan oral film

Exservan is a 50 mg oral film intended for patients who have difficulty swallowing tablets. Its excipient platform uses film-forming polymers, plasticizers, sweeteners, flavor systems, and supporting processing agents. The product is placed on the tongue, where the film dissolves without requiring a conventional tablet swallow [3].

The commercial value of the film is linked to administration convenience rather than a new riluzole mechanism. The development burden is higher than for a tablet because the manufacturer must control:

• Film thickness and weight variation
• Content uniformity
• Mechanical strength
• Folding endurance
• Disintegration or dissolution time
• Residual solvent or moisture
• Taste and mouthfeel
• Packaging protection against humidity

What excipient strategy best fits a new riluzole product?

The most attractive strategy is a targeted platform rather than a direct tablet copy. Formulators should select excipients based on the administration problem being solved.

Target product	Preferred excipient strategy	Primary development issue	Commercial rationale
Low-cost generic tablet	Conventional diluent-disintegrant-lubricant system	Bioequivalence and dissolution	Lowest manufacturing cost
Sugar-free suspension	Polymer suspender, noncaloric sweetener, flavor, preservative	Physical and microbial stability	Suitable for dysphagia and tube use
Ready-to-use unit-dose suspension	High-dose uniformity and preservative strategy	Packaging cost and stability	Improves adherence and reduces dosing errors
Oral film	Film-forming polymer, plasticizer, taste-masking system	Content uniformity and moisture sensitivity	Differentiated dysphagia product
Orally disintegrating tablet	Superdisintegrant, porous carrier, taste masking	Riluzole bitterness and tablet friability	Familiar solid-dose manufacturing
Sprinkle or multiparticulate product	Coated particles, taste-masking layer, capsule or sachet	Release control and dose uniformity	Potential for patients unable to swallow tablets
Enteral-feed-compatible suspension	Low-sedimentation system with tube compatibility	Adsorption, clogging, flushing requirements	Addresses institutional and home-care use

Which excipients should be prioritized?

A commercially practical excipient screen should begin with:

• Hypromellose, hydroxypropyl cellulose, or pullulan for films
• Xanthan gum, sodium carboxymethylcellulose, or combinations for suspensions
• Mannitol, isomalt, or erythritol for low-sugar solid formulations
• Sucralose, acesulfame potassium, or steviol glycosides for sweetness
• Polysorbates or other suitable wetting agents where needed
• Citric acid, citrate buffers, or phosphate buffers for pH control
• Sodium benzoate or other appropriate preservatives in aqueous products
• Colloidal silicon dioxide and magnesium stearate for tablet process control

Excipient selection must account for riluzole’s bitter taste, low aqueous solubility, dose size, and sensitivity to formulation pH and food-related administration conditions. A higher-viscosity suspension may improve physical stability but can impair syringe delivery and feeding-tube flow. A stronger film may improve handling but dissolve more slowly.

What formulation patents protect riluzole products?

Riluzole’s original compound and conventional tablet protection are no longer the primary commercial barriers. The relevant IP has shifted to dosage-form and administration claims.

Potentially material patent categories include:

1. Oral suspension composition claims.
2. Oral-film composition and manufacturing claims.
3. Taste-masked riluzole particles.
4. Specific polymer combinations.
5. Packaging systems that control moisture or dose uniformity.
6. Methods of administering riluzole to patients with dysphagia.
7. Enteral-tube administration methods.
8. Formulations with defined dissolution, particle-size, viscosity, or stability parameters.

The original Rilutek product was approved under NDA 20-599. Tiglutik and Exservan were approved under separate NDAs for differentiated dosage forms. The FDA Orange Book is the controlling source for current listed patents, exclusivity codes, and reference-product information [4].

IP category	Strategic status
Riluzole compound patent	Historical protection; no longer the main barrier
Conventional 50 mg tablet	Generic competition established
Suspension formulation	May support product-specific patent or exclusivity claims
Oral film	May support formulation, process, or method-of-use claims
Taste masking	Potentially narrow but relevant to differentiated products
Tube administration	Potential method-of-use or formulation claims
Manufacturing process	Relevant if it produces a defined microstructure or stability profile

Patent strength will depend on claim breadth, written-description support, enablement, prosecution history, and whether the claims cover commercially necessary excipients. A patent limited to one polymer ratio may be easier to design around than a claim covering a broad class of film-forming systems.

When does riluzole lose exclusivity?

Riluzole’s original small-molecule exclusivity has expired, and generic tablets are commercially available. The commercial question is no longer when riluzole itself loses exclusivity. It is whether product-specific patents or regulatory exclusivity delay competing suspensions, films, or other differentiated products.

FDA approval dates provide the relevant chronology:

Milestone	Product significance
1990s	Riluzole introduced for ALS treatment
1997	FDA approval of Rilutek for ALS
2018	FDA approval of Tiglutik oral suspension
2018	FDA approval of Exservan oral film
Current market	Generic tablets compete with branded differentiated dosage forms

A generic tablet applicant can generally rely on the established riluzole tablet reference standard. A suspension or film applicant may need a separate bioequivalence strategy, comparative pharmacokinetic study, in vitro performance package, or 505(b)(2) pathway, depending on the reference product and formulation differences.

What Paragraph IV challenges and generic entry risks exist?

Paragraph IV risk is highest for product-specific patents covering Tiglutik or Exservan. A challenger may assert that the patents are invalid, unenforceable, or not infringed. The commercial impact depends on:

• Whether the patent is listed in the Orange Book
• Whether the patent claims the entire dosage form or only a narrow formulation
• Whether the proposed product uses the claimed excipients
• Whether the applicant files a Paragraph IV certification
• Whether the innovator files suit within the statutory period
• Whether a 30-month stay applies
• Whether the parties settle before trial

Tablet competition has limited dependence on these product-specific patents because generic riluzole tablets already occupy the market. Suspension and film entrants face greater formulation and regulatory risk, but they can pursue design-arounds using different polymers, sweetener systems, film architectures, or packaging configurations.

Generic launch scenarios

Scenario	Likely effect
Additional generic tablets	Further price compression
Generic suspension	Pressure on Tiglutik pricing and institutional accounts
Generic oral film	Direct challenge to Exservan’s dysphagia positioning
505(b)(2) differentiated product	Potentially narrower label and higher development cost
Authorized generic or licensed product	Faster market access with lower IP risk
Non-infringing formulation design-around	Avoids selected patents but may require new clinical or bioequivalence work

A successful challenger must solve more than patent risk. It must demonstrate acceptable taste, dose accuracy, storage stability, and usability in a population with progressive swallowing impairment.

What commercial opportunities exist in riluzole excipients?

The largest opportunity is a patient-centric dosage form with strong distribution economics.

Dysphagia-focused products

ALS patients may have difficulty swallowing solid oral dosage forms. An oral film, suspension, orally disintegrating tablet, or multiparticulate product can reduce administration burden. The product must work under real-world conditions, including caregiver administration and variable saliva production.

Feeding-tube administration

A suspension designed for enteral administration could target hospitals, long-term-care facilities, specialty pharmacies, and home caregivers. Commercial claims should be supported by testing for:

• Tube compatibility
• Clogging risk
• Drug recovery after flushing
• Adsorption to tubing
• Compatibility with common enteral feeds
• Dose uniformity after storage
• Administration through different syringe sizes

A product that eliminates crushing of tablets may have practical value in institutional settings. The formulation should not require complex reconstitution or frequent preparation.

Taste-masked formulations

Riluzole’s bitterness creates an opportunity for ion-pairing, polymer coating, lipid-based taste masking, complexation, or rapid-swallow delivery. Taste masking is especially important for liquids and films because the drug contacts the oral cavity directly.

A successful taste-masking system must avoid delaying absorption or creating an inconsistent dose. Excessive polymer coating can reduce dissolution and complicate bioequivalence.

Unit-dose and adherence packaging

Unit-dose oral suspension sachets, prefilled oral syringes, and moisture-protective film pouches can support caregiver accuracy. Packaging may also create defensible IP when it is integrated with stability, dosing, or administration performance.

Global-market opportunities

The formulation needs differ by market:

Region	Commercial priority
United States	Orange Book risk, ANDA strategy, specialty-pharmacy access
European Union	Mutual recognition and decentralized procedures, dysphagia positioning
Japan	Smaller market with local dosage-form and labeling requirements
Emerging markets	Low-cost liquid or dispersible tablet, temperature stability
Institutional markets	Tube compatibility, unit dosing, low preparation burden

A room-temperature-stable liquid could have greater value in markets where cold-chain infrastructure and caregiver resources are limited. Preservative-free unit-dose systems may command higher pricing but increase packaging and manufacturing costs.

How does riluzole compare with competing ALS therapies?

Riluzole competes with edaravone and symptomatic ALS treatments, but its excipient opportunity is different.

Attribute	Riluzole	Edaravone
Molecular type	Small molecule	Small molecule
Major administration forms	Tablet, suspension, oral film	Intravenous and oral suspension products
Biosimilar exposure	None	None
Core formulation challenge	Dysphagia, taste, tube delivery	Route-specific delivery and dosing
Generic opportunity	Established for tablets	Product- and formulation-dependent
Differentiation route	Film, suspension, tube-compatible dosage forms	Oral liquid, infusion, and delivery convenience

Riluzole’s lower-cost generic tablet market limits premium pricing. A new product therefore needs measurable administration benefits, not merely a different excipient list.

How strong is the riluzole formulation patent estate?

The estate is strongest where formulation claims cover a clinically necessary combination of properties, such as rapid oral dissolution, acceptable taste, content uniformity, and stability. It is weaker where claims can be bypassed by replacing one conventional excipient with another.

Commercially meaningful claim scope may include:

• Broad classes of film-forming polymers
• Defined riluzole loading ranges
• Specific taste-masking architectures
• Suspension systems with controlled sedimentation
• Tube-compatible compositions
• Packaging and moisture-control combinations
• Manufacturing parameters that create a reproducible dosage form

A formulation patent is more valuable when it covers the product’s core performance and is difficult to design around without sacrificing usability. Conventional excipient substitutions alone usually provide limited exclusionary power.

What FDA and Orange Book issues affect development?

A sponsor should classify the proposed product before selecting the regulatory route.

ANDA pathway

An ANDA is most suitable for a product that matches an approved generic reference product in dosage form, strength, route, and key characteristics. Conventional riluzole tablets are the clearest target.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a new suspension, film, or other dosage form that relies partly on FDA findings for riluzole but differs materially from the approved tablet. The sponsor may need additional clinical pharmacology, safety, usability, or food-effect data.

Orange Book considerations

The Orange Book should be reviewed for:

• Listed patents associated with each reference NDA
• Patent-use codes
• Regulatory exclusivity periods
• Reference listed drug status
• Therapeutic-equivalence codes
• First-applicant eligibility for 180-day exclusivity

The patent analysis must distinguish patents listed against Rilutek tablets from those listed against Tiglutik or Exservan. A tablet applicant should not assume that a patent covering an oral film blocks a conventional tablet, and a film applicant should not assume that expiration of the original Rilutek patents eliminates formulation risk.

What revenue exposure and market-entry economics should investors assess?

The revenue exposure is concentrated in differentiated products rather than generic tablets.

Asset	Revenue risk from generic entry	Main defense
Generic riluzole tablet	Already exposed to price competition	Manufacturing scale and distribution
Tiglutik	Moderate to high if a suspension entrant launches	Formulation patents, brand loyalty, access contracts
Exservan	Moderate if an oral-film generic achieves approval	Film know-how, patient and caregiver preference
New tube-compatible product	Depends on clinical usability and reimbursement	Device integration, unit-dose packaging, workflow value

The most attractive launch profile is a product that can obtain specialty-pharmacy reimbursement while reducing caregiver preparation. A low-cost generic suspension may win volume but face limited margins. A film or prefilled liquid may support higher pricing if it demonstrates fewer administration errors and better persistence.

Key Takeaways

• Riluzole’s original compound protection is no longer the principal commercial barrier.
• Generic 50 mg tablets are a mature, price-competitive market.
• The strongest opportunities are oral films, tube-compatible suspensions, taste-masked liquids, and caregiver-friendly unit-dose products.
• Excipients should be selected around dysphagia, sedimentation, microbial stability, taste, moisture control, and enteral-tube performance.
• Product-specific patents associated with Tiglutik and Exservan require current Orange Book review before launch planning.
• Biosimilar risk does not apply because riluzole is a small molecule.
• Paragraph IV risk is concentrated in suspension and oral-film formulation patents.
• A commercially defensible riluzole product must combine formulation performance with a regulatory pathway and measurable administration benefit.

FAQs

Can riluzole be formulated as a pediatric liquid?

Riluzole is approved for ALS in adults, and a pediatric liquid would require an appropriate clinical and regulatory rationale. The formulation platform could be technically feasible, but pediatric labeling and dosing would require separate regulatory support.

Which riluzole dosage form is best for patients with feeding tubes?

A purpose-designed oral suspension is generally better suited than a tablet because it can be administered without crushing. Tube diameter, flushing procedure, adsorption, and dose recovery must be validated for the intended product.

Are sugar-free riluzole formulations commercially attractive?

Yes. Sugar-free and low-calorie systems can improve suitability for patients with metabolic restrictions and reduce dependence on sucrose-based taste masking. They require careful control of bitterness, viscosity, and preservative performance.

Can a new riluzole oral film avoid Exservan patents?

Potentially. A developer may use different polymers, plasticizers, loading levels, manufacturing conditions, or packaging. Freedom to operate depends on the specific claims, prosecution history, and proposed product composition.

What is the most defensible riluzole formulation opportunity?

A stable, taste-masked, unit-dose suspension or oral film with validated feeding-tube or dysphagia performance is more defensible than another conventional tablet. The strongest commercial position would combine usability data, differentiated packaging, and claims covering formulation performance.

References

1. U.S. Food and Drug Administration. (2022). Rilutek (riluzole) tablets, prescribing information. FDA. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2022). Tiglutik (riluzole) oral suspension, prescribing information. FDA. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2022). Exservan (riluzole) oral film, prescribing information. FDA. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA. https://www.fda.gov
6. U.S. Pharmacopeia. (2024). General chapter <711> dissolution. United States Pharmacopeial Convention.